Why Greenwich LifeSciences, Inc.’s (GLSI) Stock Is Down 6.57%
As of Monday, August 31, Greenwich LifeSciences, Inc.’s GLSI share price has dipped by 6.57%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Commentary & Analysis
Why Greenwich LifeSciences, Inc.’s (GLSI) Stock Is Down 7.10%
As of Friday, August 28, Greenwich LifeSciences, Inc.’s GLSI share price has dipped by 7.10%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Greenwich LifeSciences, Inc.’s (GLSI) Stock Is Up 7.22%
As of Tuesday, August 25, Greenwich LifeSciences, Inc.’s GLSI share price has surged by 7.22%, which has investors questioning if this is right time to sell.Michael Rose
Why Greenwich LifeSciences, Inc.’s (GLSI) Stock Is Up 10.64%
As of Tuesday, August 25, Greenwich LifeSciences, Inc.’s GLSI share price has surged by 10.64%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Greenwich LifeSciences, Inc.’s (GLSI) Stock Is Up 13.26%
As of Friday, August 21, Greenwich LifeSciences, Inc.’s GLSI share price has surged by 13.26%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | GLSI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $234.1 | $282.4 | 28% |
|
| Shares Out (Mil) | 14.6 | 54.0 | 26% |
|
| Institutional Ownership | 19.5% | 93.1% | 9% |
|
| Float (Mil) | 7.6 | 42.2 | 16% |
|
| Beta | 1.45 | 0.94 | 81% |
|
| Avg Daily Volume (000s) | 127 | 482 | 40% |
|
| Price Change (52-week) |
45.4% | 59.9% | 79% |
|
| Growth | GLSI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (59.2%) | (10.1%) | 5% |
|
| EPS (5yr) | (48.8%) | 15.9% | 4 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (45.1%) | (15.6%) | 9% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | GLSI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($23) | ($43) | 23% |
|
| EPS (TTM) | ($1.578) | ($1.500) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($13) | ($31) | 18% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $240 | $190 | 27% |
|
| Valuation | GLSI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 75.95 | 2.84 | 99% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | GLSI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (374.5%) | (47.7%) | 1% |
|
| ROE | (986.3%) | (55.0%) | 0% |
|
| Liabilities to Assets | 64.9% | 29.8% | 60% |
|
| F-Score | 1 | 3 | 1% |
|
Greenwich LifeSciences, Inc. did not pass any screens on 9/4/2026.
